Drug Trial Radar · NCT02768298
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
201
Actual
Start
Jul 12, 2016
Primary completion
Nov 25, 2019
Study completion Nov 25, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696Drug
LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
EnalaprilDrug
Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets. Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.
Placebo matching enalaprilDrug
Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
Placebo matching LCZ696Drug
Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of TreatmentTime frame: Baseline, 3 months
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Erfurt, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Göttingen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Koblenz, Germany
Novartis Investigative Site
Koeln-Nippes, Germany
Novartis Investigative Site
Leverkusen, Germany
Novartis Investigative Site
Ludwigsburg, Germany
Novartis Investigative Site
Ludwigshafen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Neuwied, Germany
Novartis Investigative Site
Nienburg, Germany
Novartis Investigative Site
Rotenburg an der Fulda, Germany
Novartis Investigative Site
Rüdersdorf, Germany
Novartis Investigative Site
Siegen, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Villingen-Schwenningen, Germany
Novartis Investigative Site
Worms, Germany
Novartis Investigative Site
Wuppertal, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Berlin, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.